ReviewPathogens (Basel, Switzerland)2022
Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs.
Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Associations of blood donor and product characteristics with platelet transfusion outcomes.Blood advances · 2026Article
- Pathogen Reduction of Transfused Blood Components-The End of the Beginning Rather than the Beginning of the End.Pathogens (Basel, Switzerland) · 2026Review
- Monitoring bacterial contamination of blood components at the Croatian Institute of Transfusion Medicine-Evolution of strategies and results in a 14-year period (2011-2024).Vox sanguinis · 2026Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Demand for human leukocyte antigen or human platelet antigen-selected platelets: An observational study at Canadian Blood Services.Transfusion · 2026Observational
- Pathogen inactivation of red cell concentrates and whole blood: I. History, technologies and in vitro product preservation studies.Vox sanguinis · 2026Review
- Assessing the Efficacy of Pathogen-Reduced Platelet Transfusions for Hemostasis in Children Undergoing Cardiopulmonary Bypass Surgery.The Annals of thoracic surgery · 2025Article
- Pathogen reduction diminishes the protective effects of platelets on endothelial barrier permeability in vitro.Blood vessels, thrombosis & hemostasis · 2025Article
- Platelet Transfusions: Current Practices and Emerging Alternatives in the United States.Life (Basel, Switzerland) · 2025Review
- Ultrastructure of human platelet concentrates after treatment with pathogen reduction technologies for prolonged storage.Frontiers in medicine · 2025Article
- Article
- Platelet Pathogen Reduction Technology-Should We Stay or Should We Go…?Journal of clinical medicine · 2024Article
- Increase of Phosphoprotein Expressions in Amotosalen/UVA-Treated Platelet Concentrates.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024Article
- ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage.PloS one · 2024Article
- Evaluation of bacterial safety approaches of platelet blood concentrates: bacterial screening and pathogen reduction.Frontiers in medicine · 2024Review
- Challenges for the maintaining the microbiological safety of the UK blood supply.Clinical medicine (London, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this systematic review, we evaluate the efficacy and safety of blood components treated with pathogen reduction technologies (PRTs). We searched the Medline, Embase, Scopus, Ovid, and Cochrane Library to identify RCTs evaluating PRTs. Risk of bias assessment and the Mantel-Haenszel method for data synthesis were used. We included in this review 19 RCTs evaluating 4332 patients (mostly oncohematological patients) receiving blood components treated with three different PRTs. Compared with standard platelets (St-PLTs), the treatment with pathogen-reduced platelets (PR-PLTs) does not increase the occurrence of bleeding events, although a slight increase in the occurrence of severe bleeding events was observed in the overall comparison. No between-groups difference in the occurrence of serious adverse events was observed. PR-PLT recipients had a lower 1 and 24 h CI and CCI. The number of patients with platelet refractoriness and alloimmunization was significantly higher in PR-PLT recipients compared with St-PLT recipients. PR-PLT recipients had a higher number of platelet and RBC transfusions compared with St-PLT recipients, with a shorter transfusion time interval. The quality of evidence for these outcomes was from moderate to high. Blood components treated with PRTs are not implicated in serious adverse events, and PR-PLTs do not have a major effect on the increase in bleeding events. However, treatment with PRTs may require a greater number of transfusions in shorter time intervals and may be implicated in an increase in platelet refractoriness and alloimmunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.